Nike (NYSE:NKE) has not had the kind of year that investors associate with a strong performing company. Year to date the company has underperformed the S&P 500 by a little over 20% and are that far off their 52-week high as well. With a fresh 52-week low that was established following the fiscal 2017 first quarter Nike looks pretty attractive especially when comparing their fundamentals and balance sheet with competitors Under Armour (NYSE:UA)(NYSE:UA.C) and Adidas (OTCQX:ADDYY) (OTCQX:ADDDF).
First Quarter
Investors bid down the shares following what was received as disappointing results for their first fiscal quarter. On one hand revenues increased by 8% when accounting for currency and 10% on a currency neutral basis. On the other hand their gross margin was hit by 2% due to leaving the golf industry and what is now becoming a regular issue of foreign currency exchange rates. Growth in the bottom line looked good until you peel it back and see the tax rate dropping to 2.5% from 18.4% last year was likely what helped it along. Were it not for that drop in the tax rate the slipping gross margins and rising expenses would have resulted in a very different quarter with just over $.61 in earnings per share being reported, a full six cents lower than last year’s quarter.
Hot Performing Stocks To Watch Right Now: Apricus Biosciences, Inc(APRI)
Advisors’ Opinion:
- [By Paul Ausick]
Apricus Biosciences Inc. (NASDAQ: APRI) also dropped about 38% Monday to post a new 52-week low of $0.26. Shares closed at $0.42 on Friday and the stock’s 52-week high is $3.34. Volume was more than three times the daily average of around 1.4 million shares. The company is considering its options after the U.S. FDA directed the firm to develop a new formulation for its erectile dysfunction drug, Vitaros.
- [By Chris Lange]
Apricus Biosciences Inc. (NASDAQ: APRI) has a PDUFA goal date for completion of the FDAs review of the Vitaros NDA set on February 17. Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction (ED) and a new potential entrant into the U.S. ED treatment market. So far Vitaros has been approved in Canada, Mexico and certain countries in Europe, Latin America and the Middle East. Shares of Apricus were last seen at $2.22, with a 52-week range of $0.86 to $3.49 and a consensus price target of $3.50.
- [By Alexander Bird]
Here are last week’s top-performing penny stocks:
Penny Stock Current Share Price Last Week’s Gain
Ambow Education Holdings Ltd. (NYSE: AMBO) $5.70 77.11%
Nano Dimension (Nasdaq: NNDM) $2.61 75.11%
Destination Maternity Corp. (Nasdaq: DEST) $5.79 71.84%
CLPS Inc. (Nasdaq: CLPS) $9.72 71.15%
NII Holdings Inc. (Nasdaq: NIHD) $3.20 56.33%
Viveve Medical Inc. (Nasdaq: VIVE) $3.78 51.98%
Galectin Therapeutics Inc. (Nasdaq: GALT) $9.18 41.82%
Apricus Biosciences Inc. (Nasdaq: APRI) $0.36 34.70%
Polymet Mining Corp. (NYSE: PLM) $1.01 31.13%
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) $8.20 28.46%Many investors struggle with finding stocks with this sort of breakout potential because they don’t know where to look.
Hot Performing Stocks To Watch Right Now: Zogenix, Inc.(ZGNX)
Advisors’ Opinion:
- [By Cory Renauer]
Here’s what you need to know about the catalysts that could send these stocks soaring, or plummeting, in the third quarter.
Company Market Cap Incoming Catalyst
Spark Therapeutics Inc. (NASDAQ:ONCE) $3.09 billion Clinical trial results
Zogenix, Inc. (NASDAQ:ZGNX) $1.56 billion Clinical trial results
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) $593 million PDUFA dateData source: Yahoo! Finance.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Zogenix (ZGNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Sean Williams]
The other concern is that while it may be the first to market in treating Dravet syndrome and Lennox-Gastaut syndrome, another experimental therapy is nipping at its heels. In September, Zogenix (NASDAQ:ZGNX) announced surprisingly strong phase 3 data for ZX008, a low-dose fenfluramine that absolutely blew away the placebo in Dravet syndrome patient testing. Zogenix’s lead compound led to a 72.4% reduction in convulsive seizure frequency over a 14-week period, compared to the 17.4% reduction for placebo patients.
- [By Sean Williams]
But what’s interesting about Epidiolex is that its first-to-market advantage may not hold up for too long. You see, Zogenix (NASDAQ:ZGNX)also is developing a treatment for Dravet syndrome, known as ZX008, that it plans to test on LGS patients soon. In phase 3 Dravet syndrome trials, Zogenix’s lead drug wound up demonstrating a 72.4% reduction in convulsive seizure frequency over the 14-week treatment period relative to baseline. This more than quadrupled the 17.4% reduction in convulsive seizure frequency seen in placebo patients.
- [By Max Byerly]
Zogenix (NASDAQ:ZGNX) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Friday.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Zogenix (ZGNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Hot Performing Stocks To Watch Right Now: 3D Systems Corporation(DDD)
Advisors’ Opinion:
- [By Stephan Byrd]
Private Advisor Group LLC acquired a new position in shares of 3D Systems Co. (NYSE:DDD) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 12,706 shares of the 3D printing company’s stock, valued at approximately $147,000.
- [By Ethan Ryder]
Shares of 3D Systems Co. (NYSE:DDD) have been assigned a consensus recommendation of “Hold” from the nineteen analysts that are currently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a sell rating, ten have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $11.94.
- [By Leo Sun]
But most importantly, HP entered the industrial 3D printing market in2016 with its Multi-Jet Fusion Technology printers. HP’s ambitions to compete in that sector, which it initially revealed in2014, caused shares of 3D printer makers Stratasys (NASDAQ:SSYS) and 3D Systems (NYSE:DDD) to tumble.
Hot Performing Stocks To Watch Right Now: Reaves Utility Income Fund(UTG)
Advisors’ Opinion:
- [By Stephan Byrd]
Liberum Capital restated their buy rating on shares of UNITE Group (LON:UTG) in a research note released on Friday morning.
UTG has been the topic of a number of other reports. Peel Hunt restated a buy rating and issued a GBX 870 ($11.58) price target on shares of UNITE Group in a research report on Tuesday, February 27th. Morgan Stanley raised their price target on shares of UNITE Group from GBX 710 ($9.45) to GBX 850 ($11.32) and gave the stock an equal weight rating in a research report on Tuesday, March 13th. Numis Securities restated a restricted rating and issued a GBX 892 ($11.88) price target on shares of UNITE Group in a research report on Wednesday, February 21st. Finally, JPMorgan Chase & Co. raised their price target on shares of UNITE Group from GBX 850 ($11.32) to GBX 900 ($11.98) and gave the stock a neutral rating in a research report on Wednesday, March 7th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of GBX 862.83 ($11.49).
Hot Performing Stocks To Watch Right Now: BlueLinx Holdings Inc.(BXC)
Advisors’ Opinion:
- [By Joseph Griffin]
Bitcedi (BXC) is a proof-of-work (PoW) coin that uses the
Cryptonight hashing algorithm. Its launch date was May 16th, 2016. Bitcedi’s total supply is 9,616,277 coins and its circulating supply is 5,756,371 coins. Bitcedi’s official website is bitcedi.org. Bitcedi’s official Twitter account is @bitcedis and its Facebook page is accessible here. - [By Stephan Byrd]
Bitcedi (CURRENCY:BXC) traded 0.7% lower against the US dollar during the twenty-four hour period ending at 19:00 PM E.T. on May 20th. One Bitcedi coin can currently be bought for $0.0099 or 0.00000109 BTC on popular cryptocurrency exchanges. Bitcedi has a market capitalization of $57,027.00 and approximately $0.00 worth of Bitcedi was traded on exchanges in the last 24 hours. In the last seven days, Bitcedi has traded down 28.3% against the US dollar.
- [By Max Byerly]
Bitcedi (BXC) is a proof-of-work (PoW) coin that uses the
Cryptonight hashing algorithm. Its launch date was May 16th, 2016. Bitcedi’s total supply is 9,616,277 coins and its circulating supply is 5,756,371 coins. Bitcedi’s official Twitter account is @bitcedis and its Facebook page is accessible here. The official website for Bitcedi is bitcedi.org.
Hot Performing Stocks To Watch Right Now: Aimia Inc. (GAPFF)
Advisors’ Opinion:
- [By SEEKINGALPHA.COM]
Aimia (OTCPK:GAPFF) (TSX: AIM, AIM.PR.A, AIM.PR.B, AIM.PR.C)
As some background, we are intimately familiar with Aeroplan and Air Canada (OTCQX:ACDVF) not just as investors but as extraordinarily heavy consumers. As both an Air Canada top tier elite and Aeroplan top tier member I generate well in excess of 1.5 million Aeroplan miles annually, half from flying Air Canada and its partners and the other half from spending. As consumers we were concerned with Air Canada’s decision (though we expect more details to come out that will alleviate these concerns) but as investors we understand that the fundamental business model of mileage programs are incredibly attractive and that Aimia presents an incredibly rare and lucrative investment opportunity for the investor discerning enough to dig into the company.